{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":3,"description":"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nRADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV\n\nInternal Radiation Therapy: Undergo brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nExternal Beam Radiation Therapy: Undergo EBRT\n\nLaboratory Biomarker Analysis: Correlative studies","id":"EG000","otherNumAffected":1,"otherNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"title":"Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Episodic. Grade 1-2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":6}],"term":"Anemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Skin Hyperpigmentation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1-2. Bilateral lower extremities","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":2}],"term":"Edema Limbs"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":2}],"term":"Hyperkalemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Nephrotoxicity"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Diarrhea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Shoulder Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Cough"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Peripheral Neuropathy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Fatigue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Alopecia"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 3","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":2}],"term":"Anemia"}],"timeFrame":"Up to 1 year following completion of treatment (~69 weeks total)"}